Out of the 136 individual samples mostly from HLA-typed family members which were submitted to the Vlth Complement Genetics Workshop 1989, Mainz, FRG, for C4 allotyping, 129 were analyzed by prolonged gel electrophoresis followed by immunoblotting. The blotting was performed using either a Rodger (Rg):l,2 specific monoclonal, 99H7 (provided by G. Mauff, Cologne, FRG), and/or a Chido (Ch): 1 specific monoclonal antibody (MoAb), 2B12 (provided by GJ. O’Neill, Miami, USA), and a polyclonal antihuman C4 antibody. In addition, 29 individuals from the workshop panel were tested with a third antibody, 1217, and 20 individuals with a fourth antibody, 1228 (both provided by D. Bitter-Suermann, Hannover, FRG). Due to the improved typing technique a total of 13 C4A and 16 C4B variants could be discriminated, of which some have not yet been described. Considering as a rule that all allotypes with great hemolytic activity are named CAB, the Ch:l specific antibody 2B12 is reactive with all B allotypes except C4*B11, C4*B12, C4*B13, some C4*B3, C4*B4, one C4*B5, and weakly with one C4*B6 variant. The Rg:l,2 specific antibody 99H7 recognizes all C4A allotypes except for C4*A91, one C4*A1, and some C4*A12 variants. Therefore all these allotypes mentioned may, like C4*A91, express reversed antigenicity. The two additionally tested MoAbs 1217 and 1228 reacted similar to 2B12 with one exception for each. Correlations of HLA haplotypes with C4 allotypes especially with those of reversed antigenicity are discussed.

Keywords:
C4 allotyping, Immunoblotting
This content is only available via PDF.
1990
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.